In new data from ongoing investigator-initiated trials in China, the company’s experimental CAR-T therapy, BZDS1901, demonstrated tumour shrinkage and even complete clearance in a subset of heavily pretreated patients.

Paradigm Biopharmaceuticals (ASX:PAR) has announced a new research collaboration with City, University of London, aimed at unlocking deeper insights into how its lead therapy works at the biological level.

A new analysis has found that Australia’s medical research institutes are not only advancing science but also delivering substantial economic value and strengthening the nation’s healthcare capability.

Algorae Pharmaceuticals has taken another step in its push to transform drug discovery through artificial intelligence, deepening its collaboration with the Peter MacCallum Cancer Centre in a new program aimed at validating AI-predicted drug combinations.

Cynata Therapeutics has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease.

The company announced that it has received encouraging feedback from the United States Food and Drug Administration following a recent Type C meeting, marking a significant moment in its clinical development journey.

The Auckland-based regenerative medicine company has finished its Symphony randomised controlled trial, a multi-centre study focused on treating diabetic foot ulcers, one of the most persistent and costly complications of diabetes.

Genetic Signatures has unveiled an organisational overhaul aimed at sharpening its commercial focus while significantly reducing costs, marking a pivotal moment in the company’s next phase of growth.

AusBiotech has reinforced its role as Australia’s life sciences peak body through direct engagement in national discussions shaping the future of research, development, and innovation

AusBiotech has reinforced its role as Australia’s life sciences peak body through a strong national presence at Science Meets Parliament 2026 as a first-time partner, elevating sector priorities and strengthening engagement with policymakers.

Liberty Specialty Markets has introduced a new insurance solution aimed at supporting the rapidly evolving life sciences sector across the Asia Pacific, positioning itself to address a long-standing gap in specialised coverage for the industry.

Researchers from Monash University, collaborating with Seaport Therapeutics, have unveiled a promising new way to deliver medicines orally by harnessing the body’s natural fat-absorption pathways.

The company said the deal signals a clear move from late-stage clinical development toward building the infrastructure required for a potential commercial launch of its lead diagnostic candidate, 64Cu SAR bisPSMA.

BCAL chief executive Shane Ryan described the rollout as an important milestone, highlighting the company’s collaboration with leading pathology providers to accelerate access.

Melbourne-based Amplia Therapeutics, a company focused on developing targeted cancer therapies, has released updated data from its ongoing ACCENT clinical trial. The findings point to outcomes that stand out in a disease long defined by poor prognosis and limited therapeutic breakthroughs.

Celosia Therapeutics has taken a significant step forward in the fight against amyotrophic lateral sclerosis, announcing that the first patient has been dosed in its Phase 1b clinical trial of CTx1000, an experimental genetic medicine targeting a key driver of the disease.

Radiopharm Theranostics (ASX:RAD) has reported encouraging interim results from its ongoing Phase 2b clinical trial of RAD 101, an experimental imaging agent designed to improve the detection of recurrent brain metastases.